Dialogues in Diabetes – Understanding Diabesity: Pearls and Pitfalls (Issue 1)

Author(s)/Faculty: Robert F. Kushner, MD, MS, FACP, FTOS, DABOM; Jennifer B. Green, MD; Donna H. Ryan, MD, FACP, FTOS
Release Date: 10/31/2022Expiration Date: 10/30/2023
Credit Type: CME / AANP / AAPANumber of Credits: 1.5
Content Type: ArticleProvider:
Type 2 diabetes (T2D) and obesity are responsible for a large global burden of morbidity and mortality in the form of cardiovascular disease, kidney disease, and retinopathy. Obesity is frequently a comorbidity for T2D. There is strong and consistent evidence that obesity management can delay progression from prediabetes to T2D and may be beneficial in the treatment of T2D. In patients with overweight and obese with T2D, modest and sustained weight loss has been shown to improve glycemic control and to reduce the need for glucose-lowering medications. There is an increasing need to consider pharmacological approaches to assist weight loss in the so called “diabesity” syndrome. Given the relationship between the pathogenesis of obesity and T2D as well as their significant health consequences, treatment strategies that can induce weight loss while achieving glycemic control are needed. In this 2-part CE ePublication series, Dialogues in Diabetes – Diabesity Management: Advances in Incretin-Based Multireceptor Agonist Therapy, experts in the fields of T2D and obesity will address key clinical considerations in the management of patients with T2D and obesity. This first of 2 issues, Understanding Diabesity: Pearls and Pitfalls, will focus on the interrelationship between T2D and obesity, as well as overcoming clinical inertia and the significance of early treatment intensification in the reduction of long-term risks and complications associated with both conditions. Practical weight loss strategies for patients with T2D will also be addressed.